ArticleFrontiers in medicine2025
Burden of rheumatoid arthritis in India from 1990 to 2021: insights from the Global Burden of Disease Database.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Article
- Diosgenin-mediated NF-κB and MAPK pathway modulation for osteoarthritis treatment: molecular mechanisms, bioavailability enhancement, and therapeutic applications.Inflammopharmacology · 2026Review
- Categorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers.Annals of medicine and surgery (2012) · 2025Article
- Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment.Journal of nanobiotechnology · 2025Article
- Impact of seasonal cycle on rheumatoid arthritis based on genetic and epigenetic mechanisms.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) significantly impacts individual health and society. This study aims to analyze the burden of RA in India from 1990 to 2021 and provide predictions to inform national prevention and control strategies. Methods: Utilizing data from the 2021 Global Burden of Disease (GBD) database, this study describes changes in incidence, prevalence, and disability-adjusted life years (DALY) related to RA in India from 1990 to 2021, while also observing variations across 31 geographical regions. Results: From 1990 to 2021 in India, the incidence, prevalence, and DALY rates of RA showed an increasing trend, with all age-standardized rates being significantly higher in females than in males. The age group of 65-69 years showed the highest incidence rate, while the prevalence peaked at 75-79 years. The forecast results indicate that the age-standardized incidence and DALY rates of RA in India will show an upward trend from 2022 to 2036. There were considerable differences in prevalence across different regions. In 2021, the highest male prevalence was in Uttarakhand, while Goa had the lowest. For females, Tamil Nadu had the highest prevalence, and Madhya Pradesh had the lowest. Overall, areas with high Socio-Demographic Index (SDI) showed a higher disease burden, whereas Kerala, despite a higher SDI, had the lowest burden. Conclusion: Using the GBD database, our findings show that the disease burden of RA in India is on the rise from 1990 to 2021. The prevalence of RA in different regions of India is significantly different, which may be related to local economy and development. The high prevalence of RA in Indian women requires more attention to the early diagnosis and treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.